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Abstract (198 words) 
Inactivation of the Ataxia Telangiectasia Mutated gene in chronic lymphocytic leukemia 
results in resistance to p53-dependent apoptosis and inferior responses to treatment with 
DNA damaging agents. Hence, p53-independent strategies are required to target Ataxia 
Telangiectasia Mutated-deficient chronic lymphocytic leukemia. As Ataxia Telangiectasia 
Mutated has been implicated in redox homeostasis, we investigated the effect of the Ataxia 
Telangiectasia Mutated-null chronic lymphocytic leukemia genotype on cellular responses to 
oxidative stress with a view to therapeutic targeting. We found that in comparison to Ataxia 
Telangiectasia Mutated-wild type chronic lymphocytic leukemia, pro-oxidant treatment of 
Ataxia Telangiectasia Mutated-null cells led to reduced binding of NF-E2 p45-related factor-2 
to antioxidant response elements and thus decreased expression of target genes. 
Furthermore, Ataxia Telangiectasia Mutated-null chronic lymphocytic leukemia cells 
contained lower levels of antioxidants and elevated mitochondrial reactive oxygen species.  
Consequently, Ataxia Telangiectasia Mutated-null chronic lymphocytic leukemia, but not 
tumours with 11q deletion or TP53 mutations, exhibited differentially increased sensitivity to 
pro-oxidants both in vitro and in vivo. We found that cell death was mediated by a p53- and 
caspase-independent mechanism associated with apoptosis inducing factor activity. 
Together, these data suggest that defective redox-homeostasis represents an attractive 
therapeutic target for Ataxia Telangiectasia Mutated-null chronic lymphocytic leukemia. 
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INTRODUCTION 
Chronic lymphocytic leukemia (CLL) with defective DNA damage response (DDR) is 
refractory to conventional chemotherapeutics (1). The loss of DDR occurs through 
inactivation of ATM and TP53 genes (2). ATM mutations appear in 13-16% of CLLs and are 
distributed across a large coding region encompassing 64 exons (3, 4). The loss of ATM 
function typically occurs through the combined effect of 11q deletion (monoalleic ATM loss) 
and an ATM mutation, biallelic ATM mutations, or less frequently due to the presence of a 
single mutation, capable of exerting dominant-negative effect on the remaining ATM allele 
(3,4). Compared to CLL tumours with 11q deletion only, those with inactivation of both ATM 
alleles exhibit abrogated DNA damage-induced apoptotic responses in vitro and rapid clonal 
expansion in vivo, leading to reduced overall and treatment-free survival (1). Furthermore, in 
the phase III UK CLL4 trial that compared chlorambucil with fludarabine either alone or in 
combination with cyclophosphamide, CLL patients with biallelic ATM inactivation revealed 
progression free survival inferior to tumours with a single mutation or 11q deletion, which 
was second only to tumours with loss/mutation of both TP53 alleles (5). Early cytogenetic 
studies showed that CLL progression is associated with the emergence of 11q deleted 
subclones (6). More recent reports of the dynamic nature of clonal progression has led to the 
understanding that the selective pressure imparted by DNA damaging agents favours the 
expansion of pre-existing subclones with defective DDR and consequently successive 
rounds of treatment with these agents are less effective (7, 8). There is, therefore, a need for 
therapeutic strategies that act independently of the DDR pathway that can target ATM-null 
CLL cells.  
 
ATM is a serine/threonine protein kinase activated by DNA double strand breaks (DSBs) that 
coordinates the activation of cell cycle checkpoints, DNA repair and p53-dependent 
apoptosis (9). ATM phosphorylates numerous substrates and is involved in the regulation of 
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a wide range of cellular processes. Consequently, deficiencies in any of these processes 
caused by the loss of ATM could be used as therapeutic targets (10, 11). Consistent with 
this notion, ATM-null CLL cells are defective in homologous recombination repair (HRR), a 
deficiency that can be exploited to induce tumour-specific killing via enhanced requirement 
for HRR upon PARP-inhibition (11).  
 
ATM is also implicated in redox homeostasis (12). Deregulation of redox homeostasis results 
in oxidative stress and occurs either due to increased reactive oxygen species (ROS) 
production or reduced antioxidant capacity. A principle antioxidant pathway is regulated by 
the redox sensitive transcription factor, NF-E2 p45-related factor-2 (NRF2/NFE2L2). In 
unstressed cells, low levels of NRF2 are maintained through interaction with Kelch-like ECH-
associated protein 1 (KEAP1), an adapter for the E3 ubiquitin ligase Cullin 3 (CUL3) that 
directs NRF2 for proteasomal degradation (13). Modification of redox and electrophile 
sensitive cysteine residues inhibits the substrate adaptor activity of KEAP1 allowing NRF2 
accumulation. The interaction of KEAP1 with NRF2 is further modulated by phosphorylation 
of NRF2 at serine 40 by protein kinase C (PKC) (14). Within the nucleus, NRF2 forms 
heterodimers with v-maf musculoaponeurotic fibrosarcoma oncogene homolog (MAF) 
proteins (MAF-F, G and K) and binds to antioxidant response elements (AREs) in the 
promoters of target genes such as those required for glutathione synthesis and its own 
promoter (15). This activity is regulated by the transcriptional repressor BTB and CNC 
homology 1 transcription factor (BACH1) which competes for the MAF binding partners and 
for binding to gene promoters (16). In addition, genetic models suggest that binding of Nrf-2 
and its activity are regulated by the ATM substrate, Brca1(17).  
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The most compelling evidence for the role of ATM in redox homeostasis comes from studies 
of the human radiosensitivity syndrome, Ataxia Telangiectasia (AT), where both ATM alleles 
are inactivated. Cells from these patients display increased oxidative stress as a 
consequence of elevated levels of ROS, increased oxidised/reduced glutathione 
(GSSG/GSH) ratio, diminished capacity to scavenge ROS and mitochondrial dysfunction 
(12, 18). Furthermore, ATM is directly activated by oxidative stress (19) and can exert 
antioxidant activity through regulation of the pentose-phosphate pathway (20). Recent 
evidence suggests that ATM might regulate oxidative stress through NRF2. Namely, Nrf2 
target gene expression was decreased in Atm-/- murine osteoblasts and this was rescued by 
the ectopic expression of PKC delta (PKCδ) (21).  
 
In this study, we tested the hypothesis that ATM-null CLLs have an intrinsic defect in their 
antioxidant defenses which might be exploited to induce synthetic lethality of tumour cells by 
escalating oxidative stress. We show that compared to ATM-wild type (wt) CLL, ATM-null 
CLL tumours exhibited defective NRF2-dependent antioxidant transcriptional responses, 
decreased antioxidant capacity, elevated mitochondrial ROS and increased sensitivity to 
pro-oxidants both in vitro and in vivo.  Furthermore, we demonstrate that pro-oxidant 
treatment bypassed the need for a functional DRR and induced cell death via a p53- and 
caspase-independent mechanism involving AIF. 
 
METHODS 
Patient samples and cell lines  
CLL samples were obtained from Birmingham and Bournemouth Hospitals (Supplementary 
Table S1). These comprised of 3 CLLs with monoallelic ATM loss, 1 monoallelic ATM 
mutant, 3 biallelic ATM mutants, 5 with combined ATM mutation/deletion and 3 CLLs with 
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TP53 mutations. All patient samples contained >90% tumour cells. South Birmingham Ethics 
Committee granted approval for the study.  CII, HG3 and PGA isogenic CLL cell lines 
expressing short hairpin (sh)-RNA against GFP or ATM were generated as previously 
described (11).  
 
Chemicals 
H2O2, tert-butylhydroquinone (tBHQ), N-acetyl-p-benzoquinone imine (NAPQI) and N-
phenylmaleimide (Sigma-Aldrich, MO, USA). KU-55933 (Merck KGaA, Darmstadt, 
Germany), Z-VAD-FMK (EnzoLife Sciences, Exeter, UK). Parthenolide, dimethylamino 
parthenolide (DMAPT) and DMAPT-hydrochloride (DMAPT-HCl) were isolated and prepared 
as described (Supplementary Methods, Supplementary Table S2, Supplementary Figure S1, 
S2, and S3).  
 
Quantitative RT-PCR (Q-PCR) 
SYBR-Green quantitative Real-time PCR (Life Technologies) was applied with primers 
against NRF2, NQO1, GCLM, GSR and HMOX1 (Supplementary Methods). Primers against 
β-ACTIN were used for normalisation and quantification was achieved using the comparative 
Ct method (22). 
 
XChIP 
XChIP was applied to primary CLL samples before and after treatment with 100µM tBHQ for 
6 hours using anti-NRF2 and pre-immune antisera as previously described (23, and 
Supplementary Methods). 
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Biochemical assays 
GSH was quantified using a Glutathione Assay Kit (Sigma-Aldrich).  To determine GSSG, 
GSH was first derivatised with N-ethylmaleimide (Sigma-Aldrich). Levels of NADPH and 
NADP+ were quantified using an NADP/NADPH assay kit (Abcam, Cambridge, UK). 
 
Mitochondrial ROS Assay 
Mitochondrial superoxide was detected using MitoSox Red (Life Technologies) in 
accordance with the manufacturer’s instructions and quantified using a LSR II flow cytometer 
(BD Biosciences, Oxford, UK) (Supplementary Methods).  
 
RNA knockdown 
Knockdown of gene expression in HaCat cells was achieved by transfection of siRNAs 
against ATM, KEAP1, BRCA1 or Scrambled siRNA with Oligofectamine (Life Technologies) 
in accordance with the manufacturer’s instructions (Supplementary Methods, Supplementary 
Table S4).  
 
Immunoblotting 
Immunoblotting was performed as previously described (24, Supplementary Methods).  
 
Murine xenograft 
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Animals were treated in accordance with United Kingdom Home Office guidelines, Schedule 
1. Subcutaneous tumours were initiated by injection of 5x106 CII-isogenic cell lines with and 
without stable ATM-knockdown into six week old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) 
mice. Tumours were grown for 15 days prior to treatment with 6 mg/kg parthenolide or 
vehicle via intra-peritoneal injection for 5 days.  
Primary CLL tumour cells were engrafted as previously described (25).  Briefly, 6-week old 
NSG mice were sublethally irradiated (1.25Gy) prior to intravenous co-injection of 50x106 
PBMC from an ATM-null CLL patient and 10x103 CD14+ monocytes from a healthy donor. 
After three days, mice were randomised and treated with a daily dose of either 100mg/kg 
DMAPT-HCl or vehicle by oral gavage for 9 days. Splenic tumour burden was assessed by 
FACS analysis.  
 
Statistics 
In vitro and in vivo data were analysed using paired or unpaired 2-tailed Student’s t-tests. 
Data are presented as ± standard error of the mean (SEM). 
 
RESULTS 
Defective NRF2-regulated gene expression in ATM-null CLL cells   
We have investigated the effect of ATM loss on NRF2 directed antioxidant responses by 
treating a panel of CLL tumours with H2O2 and measuring the induction of gene expression 
by Q-PCR. H2O2 induced a 1.7-3.0 fold increase in NRF2 target gene expression in ATM-wt 
tumours (n=4), whereas induction was significantly impaired in ATM-null CLLs (n=4) (Figure 
1A). Examination of previously generated expression data supported this observation (26). 
Following exposure to IR, an insult that generates ROS, up-regulation of 40 NRF2 regulated 
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transcripts was significantly (p<0.05) impaired in ATM-null CLLs (n=6) compared to ATM-wt 
CLLs (n=5) (Supplementary Figure S4A).  
 
To investigate a possible role for KEAP1 in the defective induction of NRF2 target genes in 
ATM-null CLL, KEAP1 activity was inhibited pharmacologically or by siRNA knockdown. 
Tumour cells were treated with tBHQ, the quinone radical of which is an electrophile that 
covalently modifies cysteine residues in KEAP1 preventing it from targeting NRF2 for 
degradation. In ATM-wt tumours (n=5), high dose tBHQ (100 µM) induced a 5-71 fold up-
regulation of NRF2 target genes (Figure 1B). In comparison, significantly lower expression 
(0.5-4.3 fold) was induced in ATM-null tumours (n=5). A similar differential was observed 
with low dose tBHQ (10 µM) indicating that the defective expression in ATM-null CLLs was 
not due to toxicity (Supplementary Figure S4B).  
 
In accordance with a previous report, knockdown of KEAP1 also induced the expression of 
NRF2 target genes (27). Inhibition of ATM function by siRNA-knockdown (n=3) (Figure 1C) 
or ATM-inhibitor (n=3) (Figure 1D) abolished induction of NRF2-target genes. These data 
indicated that the defective regulation of NRF2 transcripts in ATM deficient cells occurs 
downstream of KEAP1 function.  
 
Consistent with an absence of a defect in the regulation of NRF2 by KEAP1 the expression 
of NRF2 mRNA and protein was comparable in ATM-wt and ATM-null tumors 
(Supplementary Figure S4C, S4D). Following treatment with tBHQ, no difference was 
observed between ATM-wt and ATM-null CLLs regarding the change in levels of NRF2 or 
other proteins involved in this antioxidant pathway: KEAP1, BACH1 and MAF protein 
(Supplementary Figure S4D, S4E, S4F).  
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A previous study suggested that ATM regulates NRF2 through PKCδ (21). However, in 
keeping with the data from a proteomic study of ATM substrates (10), we found no 
interaction between ATM and NRF2 in co-immunoprecipitation assay (Supplementary Figure 
S5A). Furthermore, we did not detect an interaction between ATM and PKCδ and loss of 
ATM did not alter the levels of PKCδ or the levels of phosphorylated-serine on NRF2 
(Supplementary Figure S5B and S5C). 
 
Brca1 was previously found to regulate Nrf-2 transcriptional activity (17). Therefore, we next 
investigated the possibility that ATM co-operates with BRCA1 in the regulation of NRF2 
activity. We found reduced induction of antioxidant genes in cells treated with either ATM or 
BRCA1-specific siRNAs (Figure 1F and 1G). This defect was not increased by the combined 
knockdown of both genes suggesting ATM and BRCA1 may act in the same pathway that 
regulates NRF2 function.  
 
These data suggest that in CLL cells, loss of ATM-function induces a defect in NRF2 
regulated gene expression that is independent of PKCδ, KEAP1, BACH1 and MAF proteins 
and may involve co-operation with BRCA1.  
 
ATM-loss reduces binding of NRF2 to antioxidant response elements 
In the absence of any defect in the regulation of NRF2 protein levels we considered whether 
the transcriptional deregulation in ATM-null CLL tumours arises at the point of NRF2 binding 
to AREs. We used XChIP and Q-PCR to measure tBHQ-induced binding of NRF2 to an ARE 
in the promoter region of the prototypic NRF2 target gene NQO1. Consistent with the 
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observed difference in gene induction, significantly less NRF2 bound to the promoter region 
of NQO1 in ATM-null CLL compared to wild-type tumours (Figure 1E). This suggests that the 
reduced NRF2 dependent transcription in ATM-null primary CLL cells is caused by defective 
binding of NRF2 to AREs. 
 
ATM-null CLL cells exhibit reduced antioxidant capacity, elevated mitochondrial 
superoxide and increased sensitivity to pro-oxidants 
In agreement with the effect on antioxidant transcriptional responses, the level of total 
cellular glutathione was significantly lower in ATM-null compared to ATM-wt primary CLL 
(Figure 2A). This effect was recapitulated in three isogenic CLL cell lines with stable 
knockdown of ATM (Supplementary Figure S6A). 
 
The regeneration of GSH from GSSG is catalysed by glutathione reductase (GSR) utilising 
NADPH as a cofactor. In ATM-wt tumours, virtually all glutathione was in the reduced form 
(GSH) whereas in ATM-null tumours only 70% was reduced and 30% was oxidised (GSSG), 
indicating increased oxidative stress in these cells (Figure 2B). Accordingly, the pool of 
NADP+ was significantly elevated in ATM-null compared to ATM-wt CLLs (Figure 2C).  
 
A-T cells display continuous oxidative stress due to intrinsic mitochondrial dysfunction  and 
contain elevated superoxide levels (28). To determine whether ATM-null CLL cells share this 
phenotype, the levels of mitochondrial ROS were examined using the mitochondrial 
superoxide sensitive dye, MitoSox Red. Consistent with observations in A-T cells, 
mitochondrial ROS levels were significantly higher in ATM-null (n=3) than wild-type CLLs 
(n=3) (p=0.007) (Figure 2D, 2E). 
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Increased mitochondrial ROS damages the organelle promoting further dysfunction in a 
positive-feedback loop (28).  To test whether this occurs in ATM-null CLLs, tumours were 
exposed to extracellular ROS.  H2O2 induced significantly higher levels of mitochondrial 
superoxide in ATM-null CLLs (n=3) compared to wild-type CLLs (n=3) at all concentrations 
tested
 
(Figure 2E).  This suggests that the intrinsic mitochondrial dysfunction associated with 
ATM-deficiency can be further exacerbated using exogenous sources of ROS. Examination 
of mitochondrial DNA content showed that both ATM-null and ATM-wt CLL contained a 
comparable number of mitochondria but significantly more than PBMCs from normal donors 
(Supplementary Figure S6B) indicating that the increased mitochondrial ROS in ATM-null 
CLL is the result of mitochondrial dysfunction rather than mitochondrial number. 
This data suggests that ATM-null CLL cells are under greater oxidative stress than their wild-
type counterparts. 
 
ATM-null CLL cells show increased sensitivity to pro-oxidants in vitro and in vivo 
In view of the increased oxidative stress in ATM-null CLL cells, we determined if this 
translated to increased sensitivity to pro-oxidant treatment. ATM-null CLLs (n=6) were 
significantly more sensitive to H2O2 than ATM-wt CLLs (n=9) in vitro (Figure 2F). The effect 
of ATM-deficiency on H2O2-sensitivity was confirmed in a CII-isogenic cell line with stable 
knockdown of ATM (Supplementary Figure S7A). 
 
Next, we addressed the sensitivity of ATM-null and wild-type primary CLLs to NAPQI and 
parthenolide, pro-oxidants that induce oxidative stress by depleting glutathione (GSH) (29, 
30). ATM-null tumours were significantly more sensitive than wild-type to both reagents 
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(Figure 2G, 2H). The effects of H2O2, NAPQI and parthenolide were associated with 
oxidative damage, as treatment with N-acetyl cysteine (NAC), a glutathione precursor, 
protected cells (Supplementary Figure S7B, S7C, S7D).  Importantly, the tumour specific 
activity of both H2O2 and parthenolide was confirmed using PBMCs from normal donors 
(Supplementary Figure S7E, S7F). 
 
To determine if the increased sensitivity to pro-oxidants was specific to the ATM-null status 
we examined primary CLL cells with monoallelic 11q deletion or TP53 mutations. The 
sensitivity of CLLs with either genotype did not significantly deviate from wild-type CLLs 
suggesting that increased sensitivity to pro-oxidants is specifically associated with the ATM 
functional loss (Supplementary Figure S7G, S7H).  
 
The in vivo efficacy of pro-oxidant therapy on ATM-deficient CLL was examined using two 
murine xenograft models. First, a subcutaneous xenograft model of CII-isogenic cell lines 
with and without stable ATM-knockdown was established.  Parthenolide significantly 
inhibited the growth of ATM-knockdown tumours compared to either vehicle treated cells or 
to parthenolide treated wild type tumours (44.0% vs 9.7%), Figure 3A.  
Finally, an ATM-null primary CLL xenograft was established and for or systemic pro-oxidant 
treatment, dimethylamino parthenolide-hydrochloride (DMAPT-HCl), a water-soluble and 
orally bioavailable form of parthenolide (31), was generated.  Quantification of engrafted 
splenic CLL cells demonstrated that pro-oxidant therapy significantly reduced hCD19+ 
tumour cell burden (p<0.05) (Figure 3B). Furthermore, engrafted cells displayed increased 
levels of 8-oxo-dG, indicating oxidative stress was induced following pro-oxidant treatment 
(Figure 3C). 
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This data shows that pro-oxidant based therapies are effective against chemoresistant ATM-
null CLL tumours in vitro and in vivo.  
 
Pro-oxidant induced cell death in CLL is p53/caspase-independent and involves AIF 
Since the DDR is defective in ATM-null CLL, a DDR-independent pathway must be operating 
to facilitate pro-oxidant induced cell death. Consistent with this, activation of the DDR was 
not detected in either ATM-null or wild-type CLL cells following treatment with therapeutically 
effective concentrations of H2O2 (Supplementary Figure S8), NAPQI or parthenolide (data 
not shown). To elucidate the mechanism of cell death induced by pro-oxidants, ATM-null 
primary CLL tumours were treated with NAPQI or H2O2 with and without pan-caspase 
inhibitor. Caspase inhibition did not significantly affect NAPQI or H2O2-induced cell death of 
ATM-null primary CLL tumours (Figure 4A, 4B). This was confirmed by immunoblotting in 
CII-isogenic cell lines which showed that in contrast to ionising radiation, PARP1-cleavage 
was not induced by NAPQI (Figure 4C).  
 
Next, we investigated the induction of cell death by an alternative mechanism involving the 
cellular redistribution of apoptosis inducing factor (AIF). In response to stress, AIF is 
released from the mitochondria as a cleaved 57kDa pro-apoptotic protein (tAIF) which 
translocates to the nucleus where it cooperates with endonuclease G to cause large scale 
DNA fragmentation and chromatin condensation (32). In untreated cells, AIF staining 
colocalised with mitochondria (Figure 4D), whereas treatment with H2O2 led to nuclear 
translocation (Figure 4E, 4F). In agreement with the differential sensitivity of ATM-null CLL 
tumours to pro-oxidants, nuclear tAIF was induced with 10 µM H2O2 whereas in ATM-wt 
CLLs, 40 µM H2O2 was required to elicit the same effect (Figure 4F). Inhibition of AIF 
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prevented H2O2-induced digestion of genomic DNA into ∼50kb fragments, thus confirming 
the role of AIF in this process (Figure 4G).  
 
These data demonstrate that pro-oxidants induce p53 and caspase-independent cell death 
in wild-type and ATM-null CLL associated with nuclear translocation of AIF.  
 
DISCUSSION 
We show that the ATM-null phenotype in CLL can be targeted with pro-oxidant based 
therapies to induce selective killing. We demonstrate that a defect in the NRF2-directed 
antioxidant response is present in ATM-null primary CLLs. This correlated with reduced 
antioxidant capacity, increased mitochondrial ROS and increased sensitivity to pro-oxidants 
in vitro and in vivo.  Previous reports have demonstrated increased sensitivity of CLL cells to 
pro-oxidant based therapies compared to non-tumour cells, but this is the first study to 
demonstrate that this approach specifically targets the ATM-null phenotype in CLL (33, 34). 
 
Our data suggest that binding of NRF2 to target gene AREs is reduced in ATM-null CLL 
despite normal levels of NRF2, KEAP1, BACH1 and MAF proteins and normal levels of 
NRF2/MAF heterodimerisation. Previous studies indicated that reduced PKCδ levels might 
contribute to defective Nrf-2 regulation in Atm-/- mice and that NRF2 stability is regulated by 
phosphorylation at ser40 by PKC (14, 21). We observed that PKCδ and serine-
phosphorylated NRF2 levels are unaffected by the loss of ATM in CLL cells and that in 
agreement with previous proteomic screen (10), both PKCδ and NRF2 are unlikely to be 
ATM substrates.  In search for the mechanism of reduced NRF2 activity in ATM null cells we 
confirmed the role of BRCA1 in the regulation of the NRF2 antioxidant response.  
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Furthermore, by showing that the combined knockdown of ATM and BRCA1 does not cause 
further deregulation we demonstrate that ATM and BRCA1 function in the same pathway to 
regulate NRF2-antioxidant responses.  
 
Previously, we have reported that ATM-null tumours are refractory to conventional DNA 
damaging therapies due to inactivation of the p53-dependent apoptosis pathway (1, 35), 
underscoring the need for a p53-independent strategy for the treatment of these tumours. In 
this study, we found that ATM-null cells are differentially sensitive to pro-oxidants as 
reflected by the appearance of tAIF in the nuclei of these cells at lower concentrations of 
H2O2 than in ATM-wt cells. The higher level of mitochondrial superoxide in ATM-null CLLs 
indicated mitochondrial dysfunction. Pro-oxidant treatment is likely to further damage the 
mitochondria, thus triggering the translocation of AIF and p53-independent cell death.  
Recent studies also suggest AIF translocation may occur due to an increase in inducible 
nitric oxide synthase (iNOS) activity following stimulation of JNK by ROS and the 
subsequent activation of ERK1/2 (36). In addition, ROS can induce the caspase-
independent activation of the BH3 interacting domain death agonist (BID), thus leading to 
AIF translocation (37). 
 
Most importantly, using a pro-oxidant based strategy we show that ATM-null CLL cells are 
significantly more sensitive than ATM-wt tumours and non-tumour cells to agents previously 
shown to stimulate NRF2-mediated adaptation to stress (38, 39). Thus both NAPQI and 
parthenolide represent novel clinically applicable approaches for the treatment of ATM-null 
CLL. Of note, acetaminophen, the NAPQI precursor, has previously been used in a phase I 
trial for the treatment of metastatic melanoma (40) as an approach to enhance the specificity 
of anti-cancer agents which deplete glutathione. Similarly, parthenolide and its water soluble 
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derivative, DMAPT, have been shown to have activity against hematopoietic malignancies, 
including chemo-refractory CLL and acute myeloid leukemia (41, 42).  
 
Targeting oxidative stress to bypass the defect in p53-dependent apoptosis is an attractive 
therapeutic strategy for several reasons. First, genetic variations present a challenging 
problem with respect to the treatment of CLL (8, 43) and elevated oxidative stress can 
impact on disease progression by inducing oxidative DNA damage (44) and increasing the 
mutation rate that supports clonal diversity. Indeed, in CLL, oxidative stress is present early 
in the genesis of disease and is detectable at the stage of pre-malignant monoclonal B-
lymphocytosis (45).  Thus to avoid the selection of adverse subclones with ATM-deficiency 
that occurs with conventional genotoxic agents (7, 8), it is preferable to target stress 
phenotypes common to all tumour cells and, as in this case, potential mechanisms of 
diversification (46). Furthermore, elevated oxidative stress may provide a selective 
advantage for ATM-null CLL cells regarding their interactions with immune cells within 
lymphoid tissues. The activity of surrounding immune cells is suppressed by ROS and 
therefore, loss of ATM and the associated increase in ROS production may facilitate immune 
evasion (47). Finally, loss of ATM and the associated decrease in antioxidant levels may 
render the tumour cells more dependent on stromal cells for redox support (48), thus 
providing a rationale for combined therapeutic approaches with pro-oxidants and inhibitors of 
tumour/microenvironment interactions.  
 
Recently a number of p53-indendent treatments for CLL became available. These include 
use of immunomodulatory agents as well as inhibitors of B cell receptor signalling that target 
either Bruton Tyrosine Kinase (Ibrutininb) or PI3 kinase delta (Idelalisib) (49).  Pro-oxidant 
based therapies utilise oxidative stress as a cellular weakness of leukemic cells and 
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represent an example of a synthetic lethality approach. It will be of interest to determine 
whether pro-oxidants could be used in combination with new targeted treatments to increase 
the benefit for patients with the ATM-null CLL phenotype. 
 
Finally, it is important to note that the roles in DDR and oxidative stress responses denote 
two separate ATM functions. ATM is activated by oxidation of the cysteine residue at 
position 2991 in the FATC domain leading to formation of disulphide cross-linked dimers 
(19). ATM mutated at C2991 is unresponsive to oxidative stress despite normal response to 
DNA damage. This raises the possibility that certain ATM mutations may not affect DDR and 
still render a phenotype amenable for targeting by pro- oxidants.  
 
In summary, we show that the oxidative stress phenotype is a valid therapeutic target in the 
treatment of ATM-null CLL due to the intrinsic deficiencies in redox homeostasis. 
Significantly, this mode of therapy bypasses the DDR defect found in ATM-null CLL cells and 
therefore represents a feasible approach for treatment of patients that harbor these 
subclones. 
 
Acknowledgements  
We thank: the LLR and EPSRC for financial support. EPSRC Core Capability grant 
(EP/K039245/1) and Science City: Innovative Uses for Advanced Materials in the Modern 
World (AWM II) underpinned chemical analysis; Winterbourne Botanic Garden (Birmingham, 
UK) for the cultivation of Feverfew from which parthenolide was extracted; Mr Xingjian Li and 
Dr Louise Male (University of Birmingham, UK) for growing crystals and unambiguously 
establishing the stereochemistry by X-ray diffraction of parthenolide, respectively.  
19 
 
 
Authorship 
Contribution: AA and VJW designed, performed experiments, interpreted data and wrote 
manuscript; TP, ND and AS performed experiments; DTP and JSF extracted parthenolide, 
synthesised DMAPT and data analysis thereof, co-wrote portions of the manuscript and 
supplementary material; CEO and WW performed analysis; GP, HP, DO, RLD and JDH 
designed the work and wrote the manuscript; SJC, PSH, MM, GSS analysed data; AMRT, 
PM, TS designed the work, interpreted data and wrote the manuscript. 
 
References: 
1. Austen B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is 
an important determinant of the cellular response to chemotherapy and survival in patients 
with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol. 
2007;25(34):5448-5457. 
2. Trbusek M, Malcikova J. TP53 aberrations in chronic lymphocytic leukemia. Adv Exp 
Med Biol. 2013;792:109-31. 
3. Austen B, Powell JE, Alvi A, et al. Mutations in the ATM gene lead to impaired overall 
and treatment-free survival that is independent of IGVH mutation status in patients with B-
CLL. Blood. 2005;106(9):3175-3182. 
4. Navrkalova V, Sebejova L, Zemanova J, et al. ATM mutations uniformly lead to ATM 
dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin. 
Haematologica. 2013;98(7):1124-1131. 
5. Skowronska A, Parker A, Ahmed G, et al. Biallelic ATM inactivation significantly 
reduces survival in patients treated on the United Kingdom Leukemia Research Fund 
Chronic Lymphocytic Leukemia 4 trial. J Clin Oncol. 2012;30(36):4524-4532. 
6. Fegan C, Robinson H, Thompson P, Whittaker JA, White D. Karyotypic evolution in 
CLL: identification of a new sub-group of patients with deletions of 11q and advanced or 
progressive disease. Leukemia. 1995;9(12):2003-2008. 
20 
 
7. Ouillette P, Saiya-Cork K, Seymour E, Li C, Shedden K, Malek SN. Clonal evolution, 
genomic drivers, and effects of therapy in chronic lymphocytic leukemia. Clin Cancer Res. 
2013;19(11):2893-2904. 
8. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations 
in chronic lymphocytic leukemia. Cell. 2013;152(4):714-726. 
9. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling 
and cancer. Nat Rev Mol Cell Biol. 2008;9(10):759-769. 
10. Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis 
reveals extensive protein networks responsive to DNA damage. Science. 
2007;316(5828):1160-1166. 
11. Weston VJ, Oldreive CE, Skowronska A, et al. The PARP inhibitor olaparib induces 
significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood. 
2010;116(22):4578-4587. 
12. Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: the next generation of 
ATM functions. Blood. 2013;121(20):4036-4045. 
13. Kobayashi A, Kang MI, Okawa H, et al. Oxidative stress sensor Keap1 functions as 
an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell 
Biol. 2004;24(16):7130-7139. 
14. Huang HC, Nguyen T, Pickett CB. Phosphorylation of Nrf2 at Ser-40 by protein 
kinase C regulates antioxidant response element-mediated transcription. J Biol Chem. 
2002;277(45):42769-42774. 
15. Itoh K, Chiba T, Takahashi S, et al. An Nrf2/small Maf heterodimer mediates the 
induction of phase II detoxifying enzyme genes through antioxidant response elements. 
Biochem Biophys Res Commun. 1997;236(2):313-322. 
16. Dhakshinamoorthy S, Jain AK, Bloom DA, Jaiswal AK. Bach1 competes with Nrf2 
leading to negative regulation of the antioxidant response element (ARE)-mediated 
NAD(P)H:quinone oxidoreductase 1 gene expression and induction in response to 
antioxidants. J Biol Chem. 2005;280(17):16891-16900. 
17. Gorrini C, Baniasadi PS, Harris IS, et al. BRCA1 interacts with Nrf2 to regulate 
antioxidant signaling and cell survival. J Exp Med. 2013;210(8):1529-1544. 
18. Valentin-Vega YA, Maclean KH, Tait-Mulder J, et al. Mitochondrial dysfunction in 
ataxia-telangiectasia. Blood. 2012;119(6):1490-1500. 
19. Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT. ATM activation by oxidative stress. 
Science. 2010;330(6003):517-521. 
21 
 
20. Cosentino C, Grieco D, Costanzo V. ATM activates the pentose phosphate pathway 
promoting anti-oxidant defence and DNA repair. EMBO J. 2011;30(3):546-55. 
21. Li B, Wang X, Rasheed N, et al. Distinct roles of c-Abl and Atm in oxidative stress 
response are mediated by protein kinase C delta. Genes Dev. 2004;18(15):1824-1837. 
22. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) 
method. Nat Protoc. 2008;3(6):1101-1108. 
23. Nowak DE, Tian B, Brasier AR. Two-step cross-linking method for identification of 
NF-kappaB gene network by chromatin immunoprecipitation. Biotechniques. 
2005;39(5):715-725. 
24. Stankovic T, Weber P, Stewart G, et al. Inactivation of ataxia telangiectasia mutated 
gene in B-cell chronic lymphocytic leukaemia. Lancet. 1999;353(9146):26-29. 
25. Bagnara D, Kaufman MS, Calissano C, et al. A novel adoptive transfer model of 
chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood. 
2011;117(20):5463-5472. 
26. Stankovic T, Hubank M, Cronin D, et al. Microarray analysis reveals that TP53- and 
ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage 
but are distinguished by major differences in activating prosurvival responses. Blood. 
2004;103(1):291-300. 
27. Devling TW, Lindsay CD, McLellan LI, McMahon M, Hayes JD. Utility of siRNA 
against Keap1 as a strategy to stimulate a cancer chemopreventive phenotype. Proc Natl 
Acad Sci U S A. 2005;102(20):7280-7285A. 
28. Quick KL, Dugan LL. Superoxide stress identifies neurons at risk in a model of 
ataxia-telangiectasia. Ann Neurol. 2001;49(5):627-635. 
29. Hinson JA. Reactive metabolites of phenacetin and acetaminophen: a review. 
Environ Health Perspect. 1983;49:71-79. 
30. Skalska J, Brookes PS, Nadtochiy SM, et al. Modulation of cell surface protein free 
thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide. 
PLoS One. 2009;4(12):e8115. 
31. Neelakantan S, Nasim S, Guzman ML, Jordan CT, Crooks PA. Aminoparthenolides 
as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorg 
Med Chem Lett. 2009;19(15):4346-4349. 
32. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, et al. Molecular 
characterization of mitochondrial apoptosis-inducing factor. Nature. 1999;397(6718):441-
446. 
22 
 
33. Farber CM, Liebes LF, Kanganis DN, Silber R. Human B lymphocytes show greater 
susceptibility to H2O2 toxicity than T lymphocytes. J Immunol. 1984;132(5):2543-2546. 
34. Wu RP, Hayashi T, Cottam HB, et al. Nrf2 responses and the therapeutic selectivity 
of electrophilic compounds in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 
2010;107(16):7479-7484. 
35. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 
dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to 
TP53 mutation. Blood. 2001;98(3):814-822. 
36. Chowdhury AA, Chaudhuri J, Biswas N, et al. Synergistic apoptosis of CML cells by 
buthionine sulfoximine and hydroxychavicol correlates with activation of AIF and GSH-ROS-
JNK-ERK-iNOS pathway. PLoS One. 2013;8(9):e73672. 
37. Tobaben S, Grohm J, Seiler A, Conrad M, Plesnila N, Culmsee C. Bid-mediated 
mitochondrial damage is a key mechanism in glutamate-induced oxidative stress and AIF-
dependent cell death in immortalized HT-22 hippocampal neurons. Cell Death and 
Differentiation. 2011;18(2):282-292. 
38. Jeong WS, Keum YS, Chen C, et al. Differential expression and stability of 
endogenous nuclear factor E2-related factor 2 (Nrf2) by natural chemopreventive 
compounds in HepG2 human hepatoma cells. J Biochem Mol Biol. 2005;38(2):167-176. 
39. Copple IM, Goldring CE, Jenkins RE, Hayes JD, et al. The hepatotoxic metabolite of 
acetaminophen directly activates the Keap1-Nrf2 cell defense system. Hepatology. 
2008;48(4):1292-1301. 
40. Wolchok JD, Williams L, Pinto JT, et al. Phase I trial of high dose paracetamol and 
carmustine in patients with metastatic melanoma. Melanoma Res. 2003;13(2):189-196. 
41. Guzman ML, Rossi RM, Neelakantan S, et al. An orally bioavailable parthenolide 
analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 
2007;110(13):4427-4435. 
42. Steele AJ, Jones DT, Ganeshaguru K, et al. The sesquiterpene lactone parthenolide 
induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro. Leukemia. 
2006;20(6):1073-1079. 
43. Landau DA, Carter SL, Getz G, Wu CJ. Clonal evolution in hematological 
malignancies and therapeutic implications. Leukemia. 2013;28(1):34-43. 
44. Oltra AM, Carbonell F, Tormos C, Iradi A, Saez GT. Antioxidant enzyme activities 
and the production of MDA and 8-oxo-dG in chronic lymphocytic leukemia. Free Radic Biol 
Med. 2001;30(11):1286-1292. 
23 
 
45. Collado R, Oliver I, Tormos C, et al. Early ROS-mediated DNA damage and oxidative 
stress biomarkers in Monoclonal B Lymphocytosis. Cancer Lett. 2012;317(2):144-149. 
46. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-
oncogene addiction. Cell. 2009;136(5):823-837. 
47. Jitschin R, Hofmann AD, Bruns H, et al. Mitochondrial metabolism contributes to 
oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood. 
2014;123(17):2663-2672. 
48. Zhang W, Trachootham D, Liu J, et al. Stromal control of cystine metabolism 
promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 
2012;14(3):276-286. 
49. Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM. Entering the Era of Targeted 
Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician. J Clin Oncol. 
2014;32(27):3039-3047. 
50. Blocher D. n CHEF I electrophoresis a linear induction of dsb corresponds to a 
nonlinear fraction of extracted DNA with dose. Int J Radiat Biol. 1990;57(1):7-12. 
 
 
FIGURE LEGENDS 
Figure 1. Induction of the NRF2 antioxidant response is defective in ATM-null CLL 
primary tumours. (A) Q-PCR showing differentially reduced induction of transcription of the 
NRF2-target genes (NRF2, GCLM, NQO1, HMOX1 and GSR) in ATM-wt compared to ATM-
null primary CLL samples following 6 hours treatment with 100µM H2O2 and (B) 100μM 
tBHQ. (C) Q-PCR showing reduced induction of the NRF2 target genes in HaCaT cells 
following KEAP1-knockdown with and without ATM-knockdown (n=3) or (D) incubation of 
KEAP1- knockdown HaCaT cells with 10µM ATM kinase inhibitor KU-55933 (ATMi) (n=3). 
The inhibitor was added 48hrs after transfection and incubated for 24hrs. Data were 
normalised to β-ACTIN and expressed as fold-change relative to untreated cells using the 
comparative Ct method. (E) XChIP assay showing defective tBHQ-induced binding of NRF2 
to ARE in the promoter of NQO1 in ATM-null CLL cells compared to ATM-wt CLLs. XChIP 
was undertaken in accordance with the protocol described (23). DNA was 
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immunoprecipitated using anti-NRF2 antibody or Pre-immune control. Enriched DNA was 
amplified using Q-PCR and data expressed as percentage of input. (F) Q-PCR showing the 
effect of ATM and BRCA1 knockdowns on tBHQ or (G) H2O2 induced expression of NRF2 
target gene NQO1 (n=3). Statistical significance was determined using Student’s t-test, p-
values less than 0.05 (*), 0.01 (**), 0.001 (***) were considered significant. Error bars 
represent SEM. 
 
Figure 2. ATM-null CLL cells exhibit decreased antioxidant content, elevated levels of 
mitochondrial superoxide and differential sensitivity to pro-oxidant agents 
(A) Total glutathione expressed relative to the levels in ATM wild-type cells are reduced in 
ATM-null primary CLL samples. (B) The ratios of GSSG:GSH and (C) NADP+:NADPH are 
differentially increased in ATM-null primary CLL tumours. (D) Mitochondrial superoxide 
measured by flow cytometry is differentially increased in ATM-null CLL tumours treated for 1 
hour with 0-25µM H2O2. Cells were dual stained with Annexin V-APC to permit exclusion of 
double-positive cells undergoing apoptosis. A representative dot plot is shown and (E) 
quantification is presented. ATM-null CLL primary tumours show differential sensitivity 
following treatment with (F) H2O2, (G) NAPQI or (H) parthenolide for 24h. The surviving 
fraction was determined by flow cytometry (Beckman Coulter MCL-Epics flow cytometer) 
with Annexin V-FITC/propidium iodide labeling.  The statistical significance was determined 
using Student’s t-test, p-values less than 0.05 (*), 0.01 (**), 0.001 (***) were considered 
significant. Error bars represent SEM. 
 
Figure 3. ATM-null cells are targeted by pro-oxidants in vivo. 
(A) Subcutaneous xenografts of ATMshRNA (n=7) and GFPshRNA (n=7) expressing CII-
isogeneic cell lines were treated with 6mg/kg parthenolide or vehicle by intraperitoneal 
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injection for 5 days leading to a significant reduction in tumour volume. Tumour volume was 
calculated using the formula Vol = 0.5 x L x W2 before and after treatment. (B) Xenografts of 
ATM-null primary CLL were established and treated by oral gavage with vehicle (n=5) or 
100mg/kg dimethylaminoparthenolide (DMAPT) (n=5) for 9 days, leading to a significant 
reduced splenic tumour burden in DMAPT-treated animals, as determined by flow cytometry 
using antibodies against hCD19 (cl.HIB19), hCD3 (cl.SK7), hCD45 (cl.2D1) and mCD45 
(cl.30-F11) (eBioscience Inc, San Diego, CA, USA) and CountBright absolute counting 
beads (Life Technologies).  (C) Histological sections depicting differentially increased splenic 
8-oxo-dG expression in DMAPT treated xenografts. Brown labeling indicates immobilization 
of anti-hCD19 (eBioscience) and anti-8-oxo-dG (Abcam) antibodies. Nuclei were 
counterstained blue with hematoxylin and images were captured at 200x magnification. 
Statistical significance was determined using Student’s t-test, p-values less than 0.05 (*) 
were considered significant. Error bars represent SEM. 
 
Figure 4. Pro-oxidant treatment induces caspase-independent, AIF-dependent 
apoptosis.  
Representative ATM-null primary CLL tumours were treated with (A) NAPQI or (B) H2O2 for 
24h in the presence or absence of 20µM pan-caspase inhibitor (Z-VAD-FMK). The effect on 
apoptosis was analysed using Annexin-V/PI labelling and flow cytometry. (C) Isogenic CII 
CLL cell lines were treated with NAPQI with and without antioxidant (NAC) for 24h or 
irradiated (IR) and PARP cleavage induction visualised by immunoblotting. Anti-ATM 
(cl.11G12, Abcam), demonstrates ATM-knockdown and anti-ACTIN antibody (Sigma) was 
used as the loading control. (D) Immunofluorescence labelling shows colocalisation of AIF 
(rabbit anti-AIF, Santa Cruz) (green) with mitochondria (MitotrackerRed, Life Technologies) 
(red). Nuclei were counterstained with DAPI (blue). (E) ATM-wt and ATM-null primary CLL 
cells were treated with 10µM and 40µM H2O2 for 6hr and labelled with anti-AIF antibody.  
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Histogram shows quantification of cells with nuclear AIF.  (F) Immunoblot of cellular fractions 
generated from cells treated with 10µM or 40 µM H2O2 confirms increased H2O2-induced 
nuclear localisation of AIF in ATM-null CLL. (G) The AIF-inhibitor, N-phenylmaleimide (50µM 
AIFi) reduced the generation of ∼50kb DNA fragments in H2O2-treated primary CLL tumours. 
Agarose plugs containing cells treated as indicated were subjected to pulsed field gel 
electrophoresis as described (50) and the separated DNA was visualised with ethidium 
bromide.  The statistical significance was determined using Student’s t-test, p-values less 
than 0.05 (*) were considered significant. Error bars represent SEM. 




Supplementary Table S1.  Characteristics of CLL samples 
CLL samples were stratified based on ATM mutation, TP53 mutation and 11q deletion 
status and phosphorylation of the ATM  targets ATM, SMC1, p53 and KAP1 in 
response to  5Gy IR.  CLL samples were considered to be  ATM wild type (ATM-wt) if 
no mutation changes were detected by Sanger sequencing and if they exhibited a 
normal ATM-dependent response to IR. Samples were considered to be ATM mutant if 
they were found to harbour at least one mutant ATM allele and exhibit impaired ATM-
dependent responses to DNA damage.  Most ATM mutant tumours had evidence of 
biallelic ATM inactivation (caused by 11q deletion and an ATM mutation), apart from 
CLL69, where a single mutation rendered the ATM response to be defective.  
CLL 
sample TP53 mutation status ATM mutation status 
11q 
deletion 
Biallelic or 
monoallelic 
ATM 
inactivation 
ATM 
dependent 
DNA damage 
response 
CLL69 WT 6815delA A M D 
CLL124 WT 5228C/T P B D 
CLLRW WT 2282delCT, 7890delA A B  D 
CLL57 WT 2308G/T P B D 
CLLJF WT del49 TTCT A NK D 
CLL152 WT 8839A/T P B D 
CLL166 WT 8977C/T P B D 
CLL15 WT 7047C/G P B D 
CLL77 WT 1058del2, 5224G/C A B D 
CLL96 WT 5041A/G,5044G/T, ins9(exon 22) A B D 
CLLCW WT WT A A NK 
CLLHR WT WT A A N 
CLL158 WT WT A A N 
CLLRR WT  WT A A N 
CLLJW WT  WT A A N 
CLL17 WT WT A A N 
CLL133 WT WT A A N 
CLL23 WT WT A A N 
CLLLP WT  WT A A NK 
CLLJB WT  WT A A N 
CLLVM WT  WT A A N 
CLLAC WT  WT A A N 
CLLMM WT WT P M NK 
CLLBK WT WT P M NK 
CLL172 WT WT P M NK 
CLL48 658del2, 849insC WT A A NK 
CLL120 752T/G, 830del21 WT A A N 
CLL117 711G/A WT A A N 
Key: P=present; A=absent; NK=not known; WT= wild type; M=monoallelic; B=biallelic; D=defective; N=normal 
Supplementary Table S2. Comparison of PTL yield from different plant source extractions 
Entry Plant type Fresh plant 
matter (kg) 
Crude extract (g) Parthenolide 
(g) 
w/w % 
content 
1 Feverfew source 1 (Tanacetum 
parthenium)a 
4.57 19.259 1.319 0.029 
2 Golden Dwarf Feverfew 
(Tanacetum parthenium 
aureum)a 
0.076 0.213 0.061 0.080 
3 Feverfew source 2 (Tanacetum 
parthenium)b 
1.91 7.740 1.076 0.056 
4 Feverfew source 3 (Tanacetum 
parthenium)c 
5.27 21.270 1.846 0.035 
5 Tansy (Tanacetum vulgare)a 5.70 14.491 4.865 0.085 
aSeeds purchased from CN Seeds and grown under glass at Winterbourne Botanic Garden 
(Birmingham, UK) 
bSeed heads collect from plants in the Birmingham local area and grown under glass at 
Winterbourne Botanic Garden (Birmingham, UK) 
cSelf sown plants collect from the grounds of Winterbourne Botanic Garden (Birmingham, 
UK) and maintained under glass. 
 
Gene Forward Reverse 
NRF2 CGGTATGCAACAGGACATTG GTTTGGCTTCTGGACTTGGA 
NQO1 GCCGCAGACCTTGTGATATT TGAACACTCGCTCAAACCAG 
GCLM CCAGATGTCTTGGAATGCAC CCATGTCAACTGCACTTCT 
GSR ACTTGCCCATCGACTTTTTG CATCTTCCGTGAGTCCCACT 
HMOX1 CCAGGCAGAGAATGCTGAGT CTTGTTGCGCTCAATCTCCT 
β-ACTIN CACCATTGGCAATGAGCGGTTC AGGTCTTTGCGGATGTCCACGT 
Supplementary Table S3. Primer sequences for Q-PCR 
Supplementary Table S4. SiRNAs sequences for transient transfection. 
Gene Forward Reverse 
ATM Stealth siRNA (Life Technologies) Stealth siRNA (Life Technologies) 
KEAP1 GGCCUUUUGGCAUCAUGAAC[dT][dT] GUUCAUGAUGCCAAAGGCC[dT][dT] 
BRCA1-1 GCUCCUCUCACUCUUCAGU[dT][dT] ACUGAAGAGUGAGAGGAGC[dT][dT] 
BRCA1-2 AAGCUCCUCUCACUCUUCAGC[dT][dT] ACUGAAGAGUGAGAGGAGCUU[dT][dT] 
Scrambled UGUGCACGUGCCGCUCGUC[dT][dT] GACGAGCGGCACGUGCACA[dT][dT] 
Extraction and derivatisation of parthenolide 
General Information 
Commercially available solvents and reagents were used without further purification. 1H 
NMR spectra were recorded at 400 MHz on a Bruker AVIII400 NMR spectrometer at room 
temperature. 13C NMR spectra were recorded at 101 MHz on a Bruker AVIII400 NMR 
spectrometer at room temperature and are proton decoupled. All 2D NMR spectra were 
recorded on a Bruker AVIII400 NMR spectrometer at room temperature. Data was 
processed on Mestrec version 6.0.2-5475 and Topspin 2.0 (version of Nov 9th 2006). 
Chemical shifts (δ) are reported in ppm relative to residual NMR solvent peaks for 1H NMR 
and 13C NMR, coupling constants (J) are expressed in Hertz (Hz). Mass spectra were 
recorded with an electrospray MS Waters LCT time of flight Mass spectrometer or with an 
EI (GC/MS) Waters GCT Premier Time of Flight Mass Spectrometer. Infrared spectra were 
recorded on a PerkinElmer 100FT-IR spectrometer at room temperature.  
 
Extraction  
  
(3aS,9aR,10aR,10bS,E)-6,9a-Dimethyl-3-methylene-3a,4,5,8,9,9a,10a,10b-
octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-2(3H)-one (PTL)  
Fresh plant matter (detailed in Supplementary Table S2) was chopped into small                                                                   
pieces and manually stirred in water (80 ˚C, 200 gL-1) for 10 minutes.  The resulting solution   
was filtered and the filtrate extracted with chloroform (2:1 aqueous:organic). The organic 
phases were combined, dried over MgSO4and reduced in vacuo to afford a brown viscous 
oil. This was purified by column chromatography on a CombiFlash RF 200i with a 330g silica 
column cartridge, ELSD detection using an ethyl acetate/hexane gradient method to afford 
crude parthenolide as a yellow solid. Recrystallisation from hexane/ethyl acetate afforded 
parthenolide as a colourless crystalline solid. Absolute stereochemistry was confirmed by X-
ray crystallography. Crystal data: C15H20O3, M= 248.31, orthorhombic, a= 11.80140(10), b= 
11.97233(9), c= 18.82978(13) Å, U= 2660.46(3) Å3, T= 99.99(10) K, space group P212121, 
Z= 8 and Z’= 2, 25179 reflections measured, 5341 unique (Rint= 0.0225) which were used in 
all calculations. The final R1 was 0.0268 (I>2(I)) and wR(F2) was 0.0693 (all data). Flack 
parameter = 0.01(4). This structure is a polymorph of an X-ray crystal structure determined 
at room temperature with Z’= 1 published on three previous occasions; CSD ref codes: 
ARTINB, ARTINB01 and ARTINB02.1 CCDC-1012153 contains the supplementary 
crystallographic data for this structure. These data can be obtained free of charge from The 
Cambridge Crystallographic Data Centre via 
http://www.ccdc.cam.ac.uk/Community/Requestastructure/pages/DataRequest.aspx. 
 
Supplementary materials and methods 
1H NMR (400 MHz, CDCl3): δ (ppm) 6.33 (d, J = 3.7, 1H), 5.63 (d, J = 3.3, 1H), 5.21 (dd, J = 
12.1, 2.5, 1H), 3.86 (t, J = 8.6, 1H), 2.85 – 2.72 (m, 2H), 2.51 – 2.32 (m, 2H), 2.24 – 2.07 (m, 
4H), 1.79 – 1.68 (m, 4H), 1.33 – 1.20 (m, 4H).; 13C NMR (101 MHz, CDCl3): δ (ppm) 169.3, 
139.3, 134.6, 125.3, 121.2, 82.5, 66.4, 61.5, 47.7, 41.2, 36.4, 30.7, 24.2, 17.3, 17.0.; FT-IR 
(ATR): ν (cm-1) 1656.46, 1752.65, 2862.90, 2933.53, 2980.48.;MS (TOF ES+): (m/z) 249.1 
[M+H]+, 271.1 [M+Na]+, 287.1 [M+K]+.; HRMS (m/z): [M]+ Calcd for C15H20NaO3, 271.1310; 
found, 271.1311.; mp: 114-116 °C (Supplementary Figures S1A and S1B). 
 
Synthesis 
(3R,3aS,9aR,10aR,10bS,E)-3-((Dimethylamino)methyl)-6,9a-dimethyl-
3a,4,5,8,9,9a,10a,10b-octahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-2(3H)-one 
(DMAPT) Dimethylamine (2M in MeOH, 1.2 mL, 2.4 mmol, 1.5 equiv.) was added to a 
stirred solution of parthenolide (400 mg, 1.6 mmol, 1 equiv.) in MeOH (14 mL) for 21 hours 
at room temperature (Supplementary Figure S2A). The reaction mixture was reduced in 
vacuo to afford the desired compound with no further purification needed as a white solid 
(0.35 g, 74%). 1H NMR (400 MHz, CDCl3): δ (ppm) 5.21 (dd, J = 11.9, 2.2, 1H), 3.83 (t, J = 
9.0, 1H), 2.78 – 2.70 (m, 2H), 2.63 (dd, J = 13.2, 4.8,1H), 2.47 – 2.32 (m, 2H), 2.28 – 2.01 
(m, 12H), 1.70 (s, 2H), 1.69 – 1.59 (m, 1H), 1.30 (s, 3H), 1.22 (td, J = 13.0, 5.9, 1H).; 13C 
NMR (101 MHz, CDCl3): δ (ppm) 176.5, 134.7, 125.0, 82.1, 66.5, 61.5, 57.7, 47.9, 46.5, 
46.2, 41.1, 36.7, 29.9, 24.1, 17.2, 16.9.; FT-IR (ATR): ν (cm-1) 1754, 2765, 2806, 2826, 
2860, 2926.; MS (TOF ES+): (m/z) 294.2 [M+H]+.; HRMS (m/z): [M]+ Calcd for C17H28NO3, 
294.2069; found, 294.2064.; mp: 145-147 °C (Supplementary Figure S2B and S2C). 
 
1-((3R,3aS,9aR,10aR,10bS,E)-6,9a-Dimethyl-2-oxo-2,3,3a,4,5,8,9,9a,10a,10b-
decahydrooxireno[2',3':9,10]cyclodeca[1,2-b]furan-3-yl)-N,N-dimethylmethanaminium 
chloride (DMAPT-HCl) Hydrochloric acid gas was passed over a stirred solution of 
dimethylamineparthenolide (248 mg, 0.85 mmol) in Et2O (50 mL) until a white precipitate 
formed (< 5min) (Supplementary Figure S1). The reaction mixture was reduced in vacuo to 
afford the desired compound as a white solid (0.28 g, >99%, 10:1 HCl salt:free amine by 1H 
NMR spectroscopy in D4-MeOH). 
1H NMR (400 MHz, d4-MeOH): δ (ppm) 5.29 (app d, J = 
10.7, 1H), 4.17 (t, J = 9.1, 1H), 3.55 – 3.25 (m, 2H (minus overlapping residual MeOH 
CH3)), 3.13 – 3.01 (m, 1H), 3.00 – 2.76 (m, 7H), 2.49 (ddd, J = 17.9, 13.3, 5.3 Hz, 1H), 2.36 
– 1.70 (m, 10H), 1.41 – 1.10 (m, 5H).; 13C NMR (101 MHz, d4-MeOH): δ (ppm) 176.49, 
134.46, 124.80, 83.10, 65.95, 61.91, 56.14, 47.51, 43.52, 43.15, 40.38, 36.18, 28.69, 23.58, 
16.10, 15.63.; FT-IR (ATR): ν (cm-1) 1755, 2765, 2826, 2861, 2926, 3373 (broad).; MS 
(TOF ES+): (m/z) 294.2 [M+H]+.; HRMS (m/z): [M]+ Calcd for C17H28NO3, 294.2069; found, 
294.2066.; mp: 110-112 °C (Supplementary Figures S3A and S3B). 
 
Cross-linking Chromatin Immunoprecipitation (XChIP) 
XChIP was applied to 10-20x106 primary CLL cells with and without treatment with 100µM 
tBHQ for 6 hours. Following treatment, cells were harvested, washed three times in 
PBS/1µM PMSF (Sigma) and fixed in 2mM disuccinimidyl glutarate (Sigma). Cells were 
then fixed in 1% formaldehyde (Sigma) and cross-linking was terminated by incubation in 
0.116M glycine (Sigma). To generate lysates for immunoprecipitation samples were 
incubated sequentially in Cell Lysis Buffer (5mM PIPES pH 8 (Sigma), 85mM KCl 
(Sigma), 0.5% NP40 (Sigma), 1µM PMSF, Protease inhibitor cocktail (Roche)) and RIPA 
Buffer (150mM NaCl (Sigma), 1% NP40, 0.5% NaDoc (Sigma), 0.1% SDS (Sigma), 50mM 
TrisHCl pH 8 (Sigma), 1µM PMSF, Protease inhibitor cocktail for 10 minutes followed by 
sonication in a Sonomatic waterbath (Model S0375) for 1 hour. Lysates were pre-cleared 
with Protein A sepharose beads (Sigma) and incubated overnight with 5µg of antibody or 
pre-immune serum. Antibody-protein/DNA complexes were immobilised on Protein A 
sepharose beads and DNA was recovered by incubation in Proteinase K (Ambion) 
followed by extraction in phenol/chloroform/isoamyl-alcohol. SYBR-green Real-Time PCR 
was used to quantify immunoprecipitated DNA. Data was expressed as percentage of 
input DNA using the comparative Ct method.  
 
Mitochondrial ROS Assay 
 
Mitochondrial superoxide was measured using MitoSox Red (Invitrogen) and flow 
cytometry in accordance with the manufacturer’s instructions. Apoptotic cells were 
eliminated from analysis by labelling with Annexin V-APC (Invitrogen). MitoSox Red in 
non-apoptotic cells was quantified using a BD Biosciences LSR II flow cytometer with BD 
FACSDiva software. For positive and negative controls, cells were pretreated with 
50μg/ml Antimycin A (Sigma) or 5μM iron (III) 5, 10, 15, 20-tetrakis-4-carboxyphenyl 
porphyrin (FeTCPP; Frontier Scientific Inc), respectively. 
 
Immunoblotting 
 
Antibodies used for immunoblotting: mouse anti-ATM , rabbit anti–phospho-ATM 
(Rockland Immunochemicals, PA, USA), rabbit anti-SMC1, rabbit anti-phospho SMC, 
rabbit anti-KAP1, rabbit anti-phospho KAP1 (Bethyl Laboratories, TX, USA), rabbit anti-
phospho p53, rabbit anti-PARP (Cell Signaling, MA 01923, USA), rabbit anti-NRF2 (C20, 
H300), goat anti-KEAP1, rabbit anti-MafF/G/K, goat anti-BACH1, goat anti-LAM B and 
rabbit anti-AIF (Santa Cruz Biotechnology, Germany), rabbit anti-TUBB1 and mouse anti-
β-ACTIN (Sigma-Aldrich).  
 
 
1.  D.G.Leppard, M.Rey, A.S.Dreiding and R.Grieb, Helv. Chim. Acta, 1974, 57, 602: 
M.R.Uskokovic, T.H.Williams and J.F.Blount, Helv. Chim. Acta, 1974, 57, 600: 
I.M.Yusupova, B.Tashkhodzhaev and A.Mallabaev, Khim.Prir.Soedin, 1986, 788. 
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Supplementary Figure S1. (A) 1H NMR spectrum of PTL (d4-MeOH) and (B)
 13C NMR 
spectrum of PTL (d4-MeOH). 
A 
B 
Supplementary Figure S2. (A) Schematic summarising the synthesis of DMAPT-HCl from PTL. 
(B) 1H NMR spectrum of DMAPT (d4-MeOH) and (C) 
13C NMR spectrum of DMAPT (d4-MeOH) 
A 
B 
C 
Supplementary Figure S3. (A) 1H NMR spectrum of DMAPT-HCl (d4-MeOH) and (B) 
13C 
NMR spectrum of DMAPT (d4-MeOH).  
A 
B 
Supplementary Figure S4 
(A) Heatmap of previously published microarray data (22) showing the effect of ATM-null status on 
the expression of 40 NRF2-target genes in response to IR. The data is normalised to the 
expression values in untreated cells. Each column represents a different patients sample and each 
row represents a single gene. Colour changes within a row indicate expression levels relative to the 
average of the same population. Red indicates up-regulation and blue down-regulation. (B) Q-PCR 
showing defective induction of NRF2-target genes in ATM-wt and ATM-null primary CLLs tumour 
cells following 6 hours treatment with 10mM tBHQ.  (C) Dot plot comparing the ACTIN-normalised 
Ct values for NRF2 transcripts in ATM-wt and ATM-null  primary CLL cells. (D) Immunoblot and (E) 
densitometric quantification showing comparable induction of NRF2 in whole cell lysates following 
treatment with tBHQ in a panel of ATM-wt and ATM-null primary CLL tumours.  The NRF2 signal 
was normalised to b-ACTIN.  (F) Nuclear [N] and cytoplasmic [C] fractions were generated using 
primary CLL samples, DMSO treated or treated with 100mM tBHQ for 6 hours. Lysates were 
separated by SDS-PAGE and immobilised NRF2, KEAP1, BACH1 and MAF1 were visualised using 
their respective antibodies (Santa Cruz). Antibodies against Lamin B and Tubulin as loading 
controls. The results show treatment-induced NRF2-nuclear localisation and reduction in the 
nuclear levels of BACH1. The levels of NRF2, KEAP1, BACH1 and MAF1 are comparable between 
ATM-wt and ATM-null primary CLL cells. The statistical significance was determined using 
Student’s t-test, p-values less than 0.05 (*), 0.001 (***) were considered significant. Error bars 
represent SEM. 
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Supplementary Figure S5 
A)The interaction between ATM and either NRF2 or PKC following treatment with IR , 
tBHQ or H2O2 was investigated in ATM-wt and A-T derived lymphoblastoid cell lines 
(LCLs) by co-immunoprecipitation. Cells were lysed using NETN buffer (150mM NaCl, 
50mM Tris-HCl pH7.8, 1% NP40, protease inhibitor cocktail EDTA-free , 2mM MgCl2 
and 90U/ml Benzonase.  Pre-cleared lysates containing 6mg of protein were incubated 
with anti-ATM (cl.11G12, Abcam) or Pre-Immune rabbit IgG (Sigma-Aldrich) and 
antibody-protein complexes were immobilised on Protein-A sepharose beads, 
separated by SDS/PAGE and subjected to immunoblotting.  Neither NRF2 (rabbit anti-
NRF2 (C20), Santa Cruz), or PKC co-immunoprecipitated with ATM in ATM-wt or 
ATM-null LCL cells in response to oxidative stress inducing agents (10Gy IR, 100µM 
tBHQ, 100µM H2O2). B) Protein lysates from CII CLL cells treated as indicated were 
immunoprecipitated with either anti-NRF2 (H300, Santa Cruz) or Pre-Immune IgG. 
Following immunoblotting of immobilised complexes the effect of ATM inhibition on the 
level of phospho serine in immunoprecipitated NRF2 was determined. Immunoblots 
were also probed for NRF2 and small MAFS. Whole cell lysates (WCL) were loaded as 
imput controls. C) Immunoblot showing comparable expression of PKC in ATM-wt and 
ATM-null primary CLLs.  Antibody against SMC1 was used as a loading control. 
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Supplementary Figure S6 
(A) Total glutathione levels are reduced in three isogenic CLL cell lines (CII, PGA and 
HG3) with ATM knock down compared to ATM-wt counterparts. Data is expressed 
relative to the levels in ATM wild-type cells (GFP shRNA). (B) Q-PCR shows that the 
mitochondrial DNA content of both ATM-wt and ATM-null  primary CLL PBMCs is 
increased relative to normal donor PBMCs. Mitochondrial DNA was amplified (mtFw- 
CACCCAAGAACAGGGTTTGT and mtRv- TGGCCATGGGTATGTTGTTAA) and 
normalised to genomic DNA with primers for 18S rRNA (18SFw- 
TAGAGGGACAAGTGGCGTTC and 18SRv- CGCTGAGCCAGTCAGTGT) using the 
comparative Ct method. The statistical significance was determined using Student’s t-
test, p-values less than 0.05 (*), 0.01 (**) were considered significant. Error bars 
represent SEM. 
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Supplementary Figure S7 
CII isogenic cell lines exhibit increased sensitivity to (A) H2O2 when ATM is knocked-
down. Cells stably expressing the indicated shRNAs were treated with increasing 
concentrations of H2O2 for 24 hours. (B) The sensitivity of ATM-null CLL cells to H2O2, 
(C) NAPQI or (D) parthenolide was diminished by pre-treatment with 20mM NAC. (E) 
PBMCs (n=2) from normal donors were treated for 24 hours with H2O2 or (F) 
parthenolide. The sensitivity of CLLs with del 11q and TP53 mutations to H2O2 (G) and 
parthenolide (H) was also examined. Surviving fraction was determined by flow 
cytometry following staining with Annexin V-FITC and propidium iodide. The statistical 
significance was determined using Student’s t-test, p-values less than 0.05 (*), 0.01 
(**), 0.001 (***) were considered significant. Error bars represent SEM. 
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Supplementary Figure S8  
Immunoblot  showing the effect of H2O2 upon phosphorylation of ATM substrates in the 
DNA damage response (DDR) in representative ATM-wt and ATM-null primary CLL 
samples. CLL samples were treated for 6 hours with the indicated concentrations of 
H2O2. For the positive control (right, last lane), protein lysate was generated from  an 
ATM-wt sample an hour after treatment with 5 Gy ionising radiation (IR).  Data shows 
that unlike the response to IR,  ATM substrates (ATM, SMC1, KAP1 and p53) are not 
phosphorylated upon exposure to H2O2, indicating that DDR is not activated. 
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